Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Acura Pharmaceuticals ( (ACUR) ) has shared an announcement.
On December 22, 2025, Acura Pharmaceuticals amended its financing arrangements with Abuse Deterrent Pharma (AD Pharma), extending the maturity date of an amended, consolidated and restated secured promissory note from December 31, 2025 to June 30, 2026 and, in consideration, pushing out the expiration of a warrant to purchase 10 million common shares at $0.01 per share to the same June 30, 2026 date. The current disclosure also recaps that AD Pharma, which had previously converted a $6.0 million note and accrued interest into nearly 43 million Acura shares in June 2021, now directly owns about 65% of Acura’s outstanding common stock, while John Schutte, who controls AD Pharma, holds an additional 13% stake, underscoring the company’s heavy reliance on a single financing partner for ongoing operations and future product development. The amended loan schedule to the November 10, 2022 secured promissory note details a series of incremental loans through December 12, 2025, increasing the aggregate principal under this facility to $9,294,279, further entrenching AD Pharma as Acura’s primary lender and largest shareholder, with significant implications for governance, capital structure and funding flexibility.
More about Acura Pharmaceuticals
Acura Pharmaceuticals is a specialty drug developer focused on abuse-deterrent and tamper-resistant technologies, including its LIMITx and Impede platforms, aimed at improving the safety profile of opioid and other pharmaceutical products in the U.S. market.
Technical Sentiment Signal: Sell
Current Market Cap: $33K
For an in-depth examination of ACUR stock, go to TipRanks’ Overview page.